09/12/2008- A federal district court judge granted a motion to unseal hundreds of confidential documents about Zyprexa, Eli Lilly’s popular antipsychotic drug. More>>>

09/10/2008- A federal judge has granted class action status to a Zyprexa lawsuit that claimed Eli Lilly hid the drug’s serious side effects. The decision by Judge Jack B. Weinstein of Federal District Court in Brooklyn also unseals confidential documents relating to the antipsychotic medication. More>>>

09/07/2008- Insurers, labor unions and pension funds can proceed with a class-action suit that claims they were overcharged by the drugmaker, which allegedly withheld information and disseminated misinformation about the safety and effectiveness of the antipsychotic, according to a hefty, 295-page opinion by US District Court Judge Jack Weinstein. His decision comes two months after he urged Lilly to settle. More>>>

09/07/2008-Pharmaceutical company Eli Lilly concealed the risks of its schizophrenia drug Zyprexa from U.S. regulators in order to increase its profits, a former FDA official has testified in Alaska court. More>>>

09/03/2008- A new analysis of patient records in the UK confirms that prescribing antipsychotics to people with dementia is not only ethically dubious but carries a serious risk of stroke, particularly when the newer atypical antipsychotics are used. More>>>

08/29/2008- All antipsychotic drugs can increase the risk of stroke, but the risk is greatest among older patients with dementia, British researchers report. More>>>

More News ::

Zyprexa ( Zyprexa Olanzapine ) is an anti-psychotic medication that was approved in 1996 by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia. It is often prescribed for other problems such as anxiety and depression. Zyprexa is a member of a class of drugs commonly referred to as "second generation anti-psychotics" ("SGA's") or "atypical anti-psychotics." When Zyprexa ( Olanzapine ) was approved in 1996, there were 2 other such SGA medications already available on the market. Consequently, Zyprexa is considered a "me-too" drug, joining a class of existing medications prescribed for the treatment of common disorders.

The SGA's were developed as an alternative to the so-called "first generation anti-psychotics" ("FGA's"). The SGA's were designed to be more effective in the treatment of anti-psychotic disorders with fewer of the side effects generally associated with the use of FGA's.

Of six SGA's currently available, Zyprexa is the most commonly prescribed. The generic name of Zyprexa is olanzapine. Zyprexa has been prescribed to more than 14 million people in 84 countries since its approval in 1996.


In September 2003, the FDA ordered Eli Lilly to revise Zyprexa's label by adding a side effects warning that "hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical anti-psychotics." Among the more serious outcomes resulting from hyperglycemic abnormalities are diabetes, diabetic ketoacidosis, diabetic coma and, in some cases death. * Zyprexa weight gain is also a commonly reported side effect.

- Diabetes
- Diabetic Ketoacidosis
- Diabetic Coma
- Hyperosmolar Coma
- Hyperglycemia

If you are currently taking Zyprexa and have concerns about its safetly, you should consult with your doctor regarding your treatment options. Under no circumstances should you discontinue taking any medication, including Zyprexa, without first consulting with your doctor. For Zyprexa legal information contact the Zyprexa Attorneys of Ennis & Ennis, P.A. by filling out our free Zyrpexa case evaluation form or by calling the toll-free number listed below.